{"entity":{"id":"sunmo","kind":"trial","name":"SUNMO","aka":[],"tldr":"A chemotherapy-free bispecific plus ADC doublet beat salvage chemotherapy in relapsed large B-cell lymphoma.","summary":"SUNMO, trial NCT05171647 sponsored by Roche and reported in 2025, showed that a chemotherapy-free doublet of the CD20 bispecific mosunetuzumab and the CD79b antibody-drug conjugate polatuzumab vedotin beats rituximab-gemcitabine-oxaliplatin salvage chemotherapy in relapsed or refractory large B-cell lymphoma in transplant-ineligible patients. It randomised 208 patients and met its dual primary endpoints of progression-free survival and overall response, with a much higher complete response rate, in a fixed-duration outpatient regimen. OnCo links it to lymphoma, mosunetuzumab, polatuzumab vedotin and the pairing of a CD20 bispecific with a CD79b ADC. Overall survival is not yet mature, and whether the doublet is an alternative for patients not fit for CAR-T or a competitor to it is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT05171647","url":"https://clinicaltrials.gov/study/NCT05171647"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["t-cell-engager"],"targets":[],"drugs":["mosunetuzumab","polatuzumab-vedotin"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05171647","phase":"3","setting":"R/R LBCL, transplant-ineligible: mosunetuzumab + polatuzumab vs R-GemOx","sponsor":"Roche","result":"PFS improved (HR reported 2025).","started":"2022-04-25","startedType":"actual","yearReported":2025,"enrolled":208,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (dual primary)","primary":true,"unit":"months","arms":[{"name":"Mosunetuzumab + polatuzumab vedotin","n":138,"value":11.5},{"name":"R-GemOx","n":70,"value":3.8}],"hr":0.41,"ci":[0.3,0.6],"p":"<0.0001","source":"https://ascopubs.org/doi/10.1200/JCO-25-01957"},{"endpoint":"Overall response rate (dual primary)","primary":true,"unit":"%","arms":[{"name":"Mosunetuzumab + polatuzumab vedotin","value":70},{"name":"R-GemOx","value":40}],"p":"<0.0001","source":"https://ascopubs.org/doi/10.1200/JCO-25-01957"},{"endpoint":"Complete response rate","unit":"%","arms":[{"name":"Mosunetuzumab + polatuzumab vedotin","value":51},{"name":"R-GemOx","value":24}],"source":"https://ascopubs.org/doi/10.1200/JCO-25-01957"}],"replication":"Consistent with STARGLO (glofitamab + GemOx vs R-GemOx, OS benefit) for CD20xCD3 bispecific-based regimens in transplant-ineligible R/R LBCL; OS was a key secondary endpoint and is not yet mature."},"route":"/trials/sunmo/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/"},{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"pairing":[{"id":"bispecific-plus-adc-lymphoma","kind":"pairing","name":"CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)","route":"/pairings/bispecific-plus-adc-lymphoma/"}],"term":[{"id":"lymphoma-tx-bispecific-step-up","kind":"term","name":"CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one","route":"/terms/lymphoma-tx-bispecific-step-up/"}],"trial":[{"id":"polargo","kind":"trial","name":"POLARGO","route":"/trials/polargo/"}]}}